MDGL
NASDAQ
$535.69
Madrigal Pharmaceuticals Inc (MDGL)
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $678.86 (+26.73%)
Market Cap
$13B
EPS 5Y CAGR
+23.26%
Free Cash Flow Yield
-2.15%
Beta (5Y)
0.76
Price Chart
Valuation
Market Cap$13B
Forward P/E666.67
P/S10.93
P/B22.55
Profitability
Total Revenue (TTM)$1.13B
Gross Profit (TTM)$1.05B
EBITDA-$312M
Profit Margin-30.3%
Operating Margin-29.8%
EPS-$13.59
Financial Health
Debt-to-Equity62.6%
Free Cash Flow Yield-2.15%
Growth & Risk
EPS 5Y CAGR+23.26%
FCF 5Y CAGR+9.82%
Beta (5Y)0.76
Sharpe Ratio1.11